Sponsor

Mylan Bertek Pharmaceuticals

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Mylan Bertek Pharmaceuticals appears in 13 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials13
Recruiting shown0
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

13 shown
Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With HypertensionNCT00142584 · lead sponsor · 2005-08-01
COMPLETED
Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African AmericansNCT00145210 · lead sponsor · 2005-04-01
COMPLETED
A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or PlaceboNCT00158093 · lead sponsor · 2003-06-01
COMPLETED
A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With HypertensionNCT00200434 · lead sponsor · 2002-10-01
COMPLETED
A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate HypertensionNCT00200421 · lead sponsor · 2002-05-01
COMPLETED
A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive PatientsNCT00200499 · lead sponsor · 2002-03-01
COMPLETED
Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate HypertensionNCT00145236 · lead sponsor · 2001-11-01
COMPLETED
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive PatientsNCT00200460 · lead sponsor · 2001-09-01
COMPLETED
A Study of the Safety and Efficacy of Nebivolol in Hypertensive PatientsNCT00200473 · lead sponsor · 2001-09-01
COMPLETED
Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons DiseaseNCT00200525 · lead sponsor · 2001-07-01
COMPLETED
A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.NCT00145171 · lead sponsor · 2001-02-01
COMPLETED
Continued Efficacy of Apomorphine After Previous Exposure of at Least Three MonthsNCT00200512 · lead sponsor · 1999-09-01
COMPLETED
Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's DiseaseNCT00142545 · lead sponsor · 1999-07-01
COMPLETED

Drugs studied in this sponsor's trials

3 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Mylan Bertek Pharmaceuticals as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
nebivolol6
atenolol1
moxifloxacin1
nebivolol RxCUI 31555 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 6 trials atenolol RxCUI 1202 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial moxifloxacin RxCUI 139462 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor13
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.